Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
Morgan Belling(West Virginia University Hospitals), Aaron Cumpston(West Virginia University Hospitals), Xiaoxiao Lu(Ultragenyx Pharmaceutical (United States)), Sijin Wen(The University of Texas MD Anderson Cancer Center), Abraham S. Kanate(HonorHealth), Nilay Shah(Levine Cancer Institute), Michael Craig(Edith Cowan University), Alexandra Shillingburg(West Virginia University)
Cited by 27
Related Papers
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278